Navigation Links
Prospective Model Outlined Potential Time and Cost Savings of,Once-Monthly Anemia Treatment

DALLAS, Texas and NUTLEY, N.J., April 23, 2007 /PRNewswire/ -- An activity-based cost analysis demonstrated that if a renal anemia treatment administered once every four weeks replaced thrice weekly administration of epoetin alfa, hemodialysis centers may save an estimated 802 nursing hours and more than $44,000 per year per 100 patients. These data, from a multi-center prospective analysis of anemia management in hemodialysis patients, were presented today during an oral session at the American Nephrology Nurses' Association (ANNA) 38th National Symposium in Dallas, TX.

"Nephrology nurses serve a pivotal role in the care of patients with renal anemia associated with chronic kidney disease," said Sheila Doss, RN, CNN, CCRA, Nursing Director of Research, Satellite Healthcare, Inc. and one of the lead study investigators. "This analysis shows that a once-monthly anemia treatment may significantly reduce the time nurses spend managing the administration of renal anemia medication, allowing us to devote more time to other important aspects of patient care."

About the Analysis

The primary objective of this analysis was to evaluate time and associated in-center supply costs observed while administering epoetin alfa three times a week in patients with renal anemia receiving dialysis, and to model the potential time and cost savings that could be expected if patients switched to a once every four week renal anemia treatment. Researchers concluded that in- center treatment of renal anemia three times a week can be labor-intensive and expensive. The analysis showed that if 100 percent of the patients were given a renal anemia treatment that could be dosed once every four weeks, a greater than 10-fold reduction in time and a similar drop in corresponding costs associated with renal anemia management could result. The researchers noted that time savings are the major contributor to total cost savings. The second component of total cost, non-drug supply costs, are also reduced greater than 10-fold with the model of a once-monthly anemia treatment.

Chronic Kidney Disease and Renal Anemia

According to the National Kidney Foundation, 20 million Americans have chronic kidney disease (CKD) and another 20 million are at increased risk for the condition. CKD is considered a rising global epidemic because it is linked to two of the fastest-growing diseases -- diabetes and hypertension. An often under-diagnosed condition, CKD is called a disease multiplier because many of its risk factors are also complications of the disease itself, creating a relentless spiral in which one condition can lead to the exacerbation of the other and, ultimately, to death. In particular, renal anemia, diabetes and cardiovascular disease frequently play this double role.

About Roche

Hoffmann-La Roche Inc. (Roche), based in Nutley, N.J., is the U.S. pharmaceuticals headquarters of the Roche Group, one of the world's leading research-oriented healthcare groups with core businesses in pharmaceuticals and diagnostics. For more than 100 years in the U.S., Roche has been committed to developing innovative products and services that address prevention, diagnosis and treatment of diseases, thus enhancing people's health and quality of life. An employer of choice, in 2006, Roche was named one of the Top 20 Employers (Science magazine), ranked the No. 1 Company to Sell For (Selling Power), and one of AARP's Top Companies for Older Workers, and in 2005, Roche was named one of Fortune magazine's Best Companies to Work For in America. For additional information about the U.S. pharmaceuticals business, visit our websites: http://www.rocheusa.com or www.roche.us.

All trademarks used or mentioned in this release are protected by law.

CONTACT: Linda Dyson of Roche , +1-973-562-2231, ; orMonique Kelley of Manning Selvage & Lee, +1-212-468-3015, or cell,+1-609-351-5664, , for Roche linda.dyson@roche.com moniqueellen.kelley@mslpr.com

Web site: http://www.rocheusa.com/http://www.roche.us/

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Related medicine technology :

1. MedImmune Announces Positive Clinical Results at PAS Annual Meeting From Large Prospective Trial in Prevention of Serious RSV Disease
2. Gene Therapy Eradicates Pancreatic Cancer in Preclinical Trial Targeting Systems Success in Mouse Model Reported in Cancer Cell
3. ACE-011 Improves Multiple Myeloma Bone Disease in a Preclinical Model
4. Ivivis PEMF Technology Significantly Improves Neuron Survival in Parkinsons Disease Model, Study Finds
5. Mymetics HIV Vaccine Demonstrates First-Ever Production of Neutralizing IgA Antibodies in Non-Human Primate Model
6. EntreMeds Aurora Kinase Inhibitor Induces Tumor Regression in Preclinical Models
7. Targanta Study Shows Oritavancin Treatment Effective in a Mouse Model of Anthrax
8. VGX Pharmaceuticals Novel HIV and Pandemic Influenza DNA Vaccine Candidates Trigger Robust Immune Responses and Protection in Pre-Clinical Models
9. RTA 402 Shown to Inhibit STAT3 in Animal Model and Holds Significant Promise for Treating Breast Cancer
10. Alnylam Reports Results of Human Experimental Infection Model with Respiratory Syncytial Virus
11. St. Jude Study Shows Effectiveness of Peramivir in Prevention of Mortality in Mouse Model of Avian Influenza H5N1 Virus Infection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... DURHAM, N.C. , Feb. 8, 2016  Avista ... appointed Eric Setzer as Chief Financial Officer (CFO). ... over twenty years of experience in various roles within ... Avista Pharma, he served as the Executive Director of ... organization in Raleigh, NC . Previously, ...
(Date:2/8/2016)...  HemaFlo Therapeutics, Inc. announced today that the United States ... 9,119,880 covering the use of NephroFlow to treat acute kidney ... founder, said, "We are pleased to secure our rights to ... , PhD, HemaFlo,s founder, said, "We are pleased to secure ... Dale Peterson , PhD, HemaFlo,s founder, said, "We ...
(Date:2/8/2016)... 2016 Palatin Technologies, Inc. (NYSE MKT: ... therapeutics for the treatment of diseases with significant ... that the United States Patent and Trademark Office ... U.S. Patent Application Serial Number 14/313,258 (the ,258 ... treating female sexual dysfunction using the formulation and ...
Breaking Medicine Technology:
(Date:2/8/2016)... ... February 08, 2016 , ... GrassrootsHealth ... incidence rate of type 2 diabetes in the GrassrootsHealth cohort with substantially higher ... make a change in public health,” states Carole Baggerly, Director of GrassrootsHealth, “the ...
(Date:2/8/2016)... Las Vegas, Nevada (PRWEB) , ... February 08, ... ... Co-Founder at RowdMap, Inc., will be speaking on how healthcare companies can use ... project costs, manage the health of a population and intervene and capture the ...
(Date:2/8/2016)... ... February 08, 2016 , ... According to research by ... require dental technicians to be certified or obtain continuing education. To increase patient ... “What’s In Your Mouth?” campaign to inform dentists and patients about the possible ...
(Date:2/7/2016)... ... February 07, 2016 , ... ... MyDecision™ empowers employers and organizations with the tools and information to lower the ... elements to cut the cost of providing employee healthcare benefits by as much ...
(Date:2/6/2016)... ... ... US Sports Camps is proud to sponsor the Bay Area Disc Association's ... leaders, ultimate organizations, and coaches from around the US. The theme for this year’s ... of Youth and Education, describes this year YUCC as “an important conversation we must ...
Breaking Medicine News(10 mins):